This table lists all the major pharma collaborations, acquisitions and mergers agreed during June 2013.
For an indepth analysis of these deals, read ‘Pharma deals during June 2013’
| Licensor acquired / licensee acquirer | Deal type | Product / technology | Headline ($m) |
| Pfizer (Wyeth) + Takeda / Teva + Sun Pharmaceutical | Patent settlement | Infringement of Protonix patent | 2,150 |
| Pearl Therapeutics / AstraZeneca | Acquisition | Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III) | 1,150 |
| Conceptus / Bayer | Acquisition | Bayer acquires >90 per cent shares includes the product Essure, for non-surgical permanent birth control (marketed) | 1,100 |
| Merck / Aspen | Acquisition | Aspen acquires Merck drugs/ manufacturing business | 1,000 |
| Aragon Pharmaceuticals / J&J | Acquisition | Includes ARN 509 (second generation androgen receptor signalling inhibitor) for castration-resistant prostate cancer (phase II) | 1,000 |
| MorphoSys / Celgene | Strategic collaboration | Joint development and co-promotion of MOR 202 in multiple myeloma (phase I/II) | 818 |
| CytomX / Pfizer | Collaboration and exclusive licence to selected PDCs | Collaboration for Probody Drug conjugates (PDCs) in oncology (platform) | 635 |
| MorphoSys / GSK | Licence to develop and commercialise | MOR 103 (HuCA-derived MAb against GM-CSF), for mild to moderate RA (phase I/II) | 580 |
| Seattle Genetics / Bayer HealthCare | Collaboration for development and commmercialisation | Auristatin based antibody-drug conjugate (ADC) technology for certain oncology targets (platform) | 520 |
| Cytokinetics / Astellas | Exclusive licence to develop and commercialise | Collaboration for therapies associated with muscle weakness and rights to CK 2127107 (phase I) for certain indications; | 490 |
| Immunocore / Genentech | Research collaboration and licence | Discovery and development of multiple targets using Immunocore’s ImmTAC technology (platform) | 320+ |
| Medicines360 / Actavis* | Licence | US commercial rights to LNG20 Intrauterine Device (IUD) (phase III) | 175 |
| MicroDose Therapeutx / Teva | Acquisition | Acquisition of inhalation technology including MDT-637 for RSV (phase II) | 165 |
| Novartis / Questcor* | Development rights | Rights to develop Synacthen (tetracosactide, melanocortin receptor agonist) and Synacthen Depot (approved in Europe for autoimmune & inflammatory conditions) | 135 |
| Fera / Perrigo | Product portfolio acquisition | Ophthalmic sterile ointment and solution product portfolio | 129 |
| Cytokinetics / Amgen** | Extension of existing licence to Japan | Small molecules to activate heart muscle, including omecamtiv mecarbil (phase II) | 75 |
| Taiwan Liposome Company / SciClone Pharmaceuticals*** | Exclusive licence | Commercialisation of ProFlow (lipid emulsion-based formulation of alprostadil) for peripheral arterial disease (approved Taiwan) | 39.5 |
| BioLineRx / Jiangsu Chia-tai Tianqing Pharmaceutical (CTTQ)† | Collaboration and licence | BL8030, second generation protease inhibitor in development for Hepatitis C (preclinical) | 30 |
| Isconova / Novavax | Acquisition | Proprietary vaccine adjuvant technology | 30 |
Unless noted, transactions are for global rights
* US only
** Japan only
*** China, Hong Kong and Macau
† China and Hong Kong